Acamprosate in the Treatment of Binge-Eating Disorder

NCT00511940 ↗

Phase 2/3 Completed 40 enrolled Lindner Center of HOPE Forest Laboratories · collab University of Cincinnati · collab

RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this research study is to determine the efficacy (how well it works), tolerability and safety of acomprosate compared with placebo in patients with binge eating disorder.

Timeline

Start: 2007-04
Primary completion: 2011-01
Completion: 2011-01

Outcome

Missed primary endpoint

paper acamprosate was not associated with a significantly greater rate of reduction in binge eating episode frequency or any other measure in the primary longitudinal analysis PMID 21080416 ↗

Publications

Results McElroy SL, Guerdjikova AI, Winstanley EL, O'Melia AM, Mori N, McCoy J, Keck PE Jr, Hudson JI. Acamprosate in the treatment of binge eating disorder: a placebo-controlled trial. Int J Eat Disord. 2011 Jan;44(1):81-90. doi: 10.1002/eat.20876.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Acamprosate	Small molecule	999 mg	Oral
Subject	Acamprosate	Small molecule	2997 mg	Oral